The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer
Clinical trial NCT07257653 · RECRUITING
Trial details
- NCT number
- NCT07257653
- Sponsor
- Zhejiang University
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-10-21
- Primary completion
- 2026-12-31
- Enrollment
- 70
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.